Would an insight into the platforms being used for predictive toxicology and those used for safety screening be valuable to you?
Amy Pointon at AstraZeneca delivered a presentation highlighting just these topics during the Stem Cells for Drug Discovery Track at the 2012 World Stem Cell and Regenerative Medicine Congress .
Amy looked at;
- recent advances in human embryonic and induced pluripotent stem cell technology and how it represents a new opportunity for assessing cardiac drug safety
- developments of these systems to high through-put screening
- the utility to provide mechanistic insight into toxicity and future advances
If you want to know the details DOWNLOAD the presentation today!
Do you want to know more?